Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia 1Blast Crisis 1

Interventions

Cyclophosphamide 58Peripheral Blood Stem Cell Transplantation 48fludarabine phosphate 44Busulfan 38Tacrolimus 35Methotrexate 32Mycophenolic Acid 31Antilymphocyte Serum 29Cyclosporine 28Filgrastim 27Whole-Body Irradiation 25Radiotherapy 23Etoposide 19Cytarabine 19Methylprednisolone 18Melphalan 17Cord Blood Stem Cell Transplantation 17Flow Cytometry 13Thiotepa 10Therapeutics 10Sirolimus 9Dasatinib 9merphos 8Psychiatric Rehabilitation 8Prednisone 8Imatinib Mesylate 8Carboplatin 8sargramostim 7fludarabine 7Vorinostat 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Blast Crisis × irofulven × Lymphoid × Clear all
NCT00003997 2013-02-08

6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia

National Cancer Institute (NCI)

Phase 1 Completed
25 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡